All In Biotech

Drug Trial Radar · NCT00804115

The International Collaborative Exfoliation Syndrome Treatment Study

Last checked: Nov 19, 2026Latest source record: Dec 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 277 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

277

Actual

Start

Aug 2000

Primary completion

Sep 2007

Study completion Dec 2008

Sponsor

Lead sponsor
The New York Eye & Ear InfirmaryAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
Dec 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Purpose: To determine the efficacy of treatment with latanoprost in combination with pilocarpine versus timolol or timolol/dorzolamide fixed combination (Timoptic or Cosopt) in eyes with XFS and elevated intraocular pressure (IOP). Methods: This is a randomized, open-label study to test the hypothesis that improving both pressure-dependent and pressure-independent aqueous outflow and minimizing iridolenticular friction will interfere with the progression of XFS, allow improvement in trabecular function, and be more effective over time than simply reducing aqueous formation. Randomization was performed across the centers, per patient rather than per eye to avoid any crossover effect caused by aqueous suppressants. Group I was treated with latanoprost and pilocarpine, both in the evening, and Group II with Timolol or Cosopt b.i.d. Only one eye per patient was randomized. Patients were followed for 2 years with assessment of IOP, visual field progression, tonographic outflow coefficient and trabecular pigmentation at the 6:00 and 12:00 position.

Conditions

  • Exfoliation Syndrome
  • Glaucoma
  • Ocular Hypertension

Interventions

  • Latanoprost with Pilocarpine vs Timolol or CosoptDrug

    Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Latanoprost combined with pilocarpine (L-PILO) should be as effective as timolol or Cosopt in lowering IOPTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New York Eye and Ear Infirmary

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.